Literature DB >> 33717863

Neuromeningeal cryptoccocosis revealing IgA-λ multiple myeloma.

Latifa Mtibaa1, Imen Beji2, Manel Ayoub3, Nawel Baccouchi1, Souha Hannechi2, Zied Aouni3, Rym Abid2, Chakib Mazigh3, Riadh Battikh2, Boutheina Jemli1.   

Abstract

Cryptococcosis is an opportunistic fungal infection that is commonly associated with an immune-compromised state. Cases of cryptococcosis have rarely been reported in patients with multiple myeloma (MM). However, cryptococcosis as a presenting symptom of MM has never been reported. We presented here a case of neuromeningeal cryptococcosis in a patient without underlying diseases, who has revealed IgA-λ MM. Early detection and treatment of cryptococcosis are essential to reduce morbidity.
© 2021 The Authors.

Entities:  

Keywords:  Cryptococcosis; Cryptococcus; Multiple; Myeloma

Year:  2021        PMID: 33717863      PMCID: PMC7932882          DOI: 10.1016/j.mmcr.2021.02.005

Source DB:  PubMed          Journal:  Med Mycol Case Rep        ISSN: 2211-7539


Introduction

Cryptococcosis is an opportunistic infection due to capsulated basidiomycetous yeast genus Cryptococcus found in the environment [1,2]. Two species Cryptococcus neoformans and Cryptococcus gattii are mainly responsible for human disease. It is the third most common invasive fungal infection after candidiasis and aspergillosis and continues to be a source of morbidity and mortality among immunocompromised hosts [3]. High mortality in Cryptococcosis approximately up to 20% is seen in immunosuppressive conditions [3]. It usually occurs in patients infected with the human immunodeficiency virus (HIV) [1,2,4]. Although, it is increasingly reported in non-HIV immunocompromised hosts such as solid organ transplantation, systemic lupus erythematosus, malignancy, sarcoidosis cirrhosis and prolonged treatment with corticosteroids [1,3]. Approximately 20% of patients who have cryptococcosis without HIV infection, have no apparent underlying disease or risk factor. A potential association with polymorphisms in immunoglobulin genes and mannose binding protein gene and infection is reported in patients without apparent immunosuppression [3,4]. Cases of cryptococcosis have been rarely reported in patients with multiple myeloma (MM) [5]. However, cryptococcosis as a presenting symptom of MM, has never been reported. We report a case of neuromeningeal cryptococcosis in a patient without any apparent underlying conditions, who was consequently diagnosed with IgA- λ MM.

Case

A 63-year-old man with a history of Biermer anemia, who has been suffering from chronic headache for 2 months with associated asthenia, anorexia, and deterioration of his general condition. Three weeks after the beginning of the headaches, the patient developed morning and postprandial jet vomiting and a fever of 38.5 °C. Physical examination showed an asthenic patient, oral trush, bilateral VI nerve paralysis, and bilateral hearing loss and was hospitalized (day 0). The laboratory data revealed increased levels of C-reactive protein (34 mg/l), sedimentation rate (65 mm/hour), and fibrinogen (4.37 g/l) and a low Hb (11 g/dl) and lymphopenia (850/mm3). A CT-cerebrum sinuses as well as a cerebral MRI were performed and were both normal. Fundoscopy showed bilateral papillary edema (stage I). Lumbar puncture on day 0 showed a CSF pressure of 35 cm H2O, a pleiocytosis of 60/mm3 (80% lymphocytes), low glucose of 0.3 mmol/l, and increased protein of 0.69 g/l. Direct examinations with Ziehl Neelsen and Gram were negative. India ink stain of the CSF showed encapsulated yeasts (Fig. 1). Culture on Sabouraud medium was positive after 3 days of incubation at 37 °C (Fig. 2). Species identification and antifungal susceptibility were performed respectively by Vitek® 2 YST-ID and AST-YS08 cards. Cryptococcus neoformans was identified and was susceptible to amphotericin B, fluconazole and flucytosine. Latex agglutination assay (PastorexTM Crypto Plus) was positive in both serum and CSF with a titer of 1/10,000 and 1/1000, respectively. A diagnosis of cryptococcal meningitis was made. Blood, sputum and urine cultures were negative for Cryptococcus.
Fig. 1

Direct examination of the centrifugation pellet of CSF (×40 objective) with India.

Fig. 2

Culture of Cryptococcus neoformans on Sabouraud medium showing beige mucous colonies after 3 days of incubation at 37 °C.

Direct examination of the centrifugation pellet of CSF (×40 objective) with India. Culture of Cryptococcus neoformans on Sabouraud medium showing beige mucous colonies after 3 days of incubation at 37 °C. To investigate potential underlying immunodeficiency, the following tests were performed: HIV 1 and HIV 2 serology was negative; thoraco-abdominopelvic CT was normal; serum protein electrophoresis showed hypoalbuminemia of 33.3 g/l and hypogammaglobulinemia of 4.9 g/l and immunofixation of serum and urine proteins showed an IgA λ peak (Fig. 3). The concentration of serum-free light chains showed λ light chains of 400 mg/l (reference range: 5.71–6.3 mg/l) with κ/λ ratio of 0.05 (reference range: 0.26–1.65). Myelogram showed a dystrophic plasmocytosis of 12%. Beta2 microglobulin was increased to 3.82 mg/l (reference range: 0.8–3 mg/l). The CD4 T cell count was 245/mm3 with CD4/CD8 ratio of 1.5.
Fig. 3

Electrophoresis immunofixation of serum protein (A) and urine protein (B) revealing an IgA λ peak.

Electrophoresis immunofixation of serum protein (A) and urine protein (B) revealing an IgA λ peak. The patient was treated with amphotericin B-deoxycholate (0.7 mg/kg/day) and flucytosine (100 mg/kg/day) starting on day 0, with repeated lumbar punctures to lower the CSF pressure under 20 cmH2O. The duration of induction treatment was 21 days and resulted in sterilisation of the CSF and a decrease of antigen titers in both CSF and blood to 1/10. Clinically, the headache disappeared, but no improvement was seen in his bilateral hearing loss and loss of vision. Consolidation treatment was started at day 22, with fluconazole 800 mg/day for 12 weeks, followed by maintenance therapy with fluconazole 200mg/day for six months with good outcome.

Discussion

Only few reports of cryptococcosis in patients with MM have been noted which is most likely due to the fact that cell-mediated immunity is relatively intact even though humoral immunity is significantly deficient [5]. Table 1 summarizes all reported cases of cryptococcosis with underlying MM [[5], [6], [7], [8], [9], [10]]. We noticed that all of the cases developed cryptococcosis at a late stage of the disease after chemotherapy, prolonged high dose corticosteroids, or stem cell transplantation, reducing CD4 cell counts and inversion of CD4/CD8 ratio [5,6]. However, cases of neuromeningeal cryptococcosis in patients with a CD4 count greater than 200/mm3 have been reported [1,11]. In our case, neuromeningeal cryptococcosis occurred in an apparently healthy patient allowing the discovery of MM. He didn't take any immunosuppressive medication and his CD4 cell count was 245/mm3.
Table 1

Overview of cases reporting cryptococcosis with MM.

Author/year [reference]age/sexType of myeloma/TreatmentCryptococcal infectionDiagnosisOutcome
Current case63 years/MIgA-λ MM/NoneMeningitisIndia ink CSF (+)CrAg in serum 1/10,000 (+) and in CSF 1/1000 (+)Survived
Mendpara SD 2002 [5]42 years/FIgG-κ type MM stage III B/chemotherapy, corticosteroids, autologous SCTMeningitisIndia ink CSF (+)CrAg in CSF 1/512 (+)Survived
Fickweiler W. 2009 [6]61 years/FMM/chemotherapy, corticosteroids, autologous SCTCerebellitisIndia ink CSF (+)+ CSF culture (+)Survived
Ludovic Suner 2014 [7]77 years/FIgA-λ MM stage III/chemotherapy, corticosteroidsDisseminated in bone marrowBone marrow histopathologic examination (fungal cells)+India ink CSF (+)+ CrAg in serum (+)Died
Richard A. Ferraro 2016 [8]64 years/MIgG-κ MM/chemotherapy, corticosteroidsInvasive sinusitisbiopsies of sinuses (+)CrAg in serum 1/64 (+)Survived
Stella J. Bowcock 2017 [9]75 years/FMM/chemotherapy, corticosteroidsMeningitisCrAg in CSF 1/1280 (+) and in serum 1/640 (+)Died
79 years/MIgM MM/chemotherapy, corticosteroidsFungemiablood culture (+)Died
Shuku Sato 2019 [10]62 years/FIgG-λ type MM stage III/chemotherapy, corticosteroidsMeningitis + FungemiaIndia ink CSF (+)CrAg in CSF and serum (+) blood and CSF cultures (+)Died

MM: multiple myeloma, SCT: Stem cell transplantation, CSF: cerebrospinal fluid, CrAg: cryptococcal antigens.

Overview of cases reporting cryptococcosis with MM. MM: multiple myeloma, SCT: Stem cell transplantation, CSF: cerebrospinal fluid, CrAg: cryptococcal antigens. Environmental factors such as prolonged and regular contact with animals, especially pigeons, are risk factors of cryptococcosis [4,11]. Only later at our patient's resumption of interrogation, we discovered that his son was a breeder of pigeons in the garden of the house, likely the source of infection in our patient. Cr Ag may be detected by latex agglutination, enzyme immunoassays, or lateral flow assay [3]. In patients with cryptococcal meningitis, the sensitivity and specificity of latex agglutination is 93%–100%, and 93%–98%, respectively which is significantly better than India ink staining and CSF cytology in the early diagnosis of neuromeningeal cryptococcosis [3,12]. CSF culture on Sabouraud medium after 48–72 hours’ incubation at 30 °C–35 °C in aerobic conditions give white to cream colonies that may turn orange tan or brown after prolonged incubation [3]. It usually takes 1 or 2 weeks to be positive but should be held for up to 4 weeks, particularly for patients receiving antifungal treatment [1,3]. According to the IDSA guidelines, the treatment of choice for induction therapy is intravenous deoxycholate amphotericin B with flucytosine for at least 2 weeks [13,14]. We presented here the first case of neuromeningeal cryptococcosis revealing IgA- λ MM in an early stage. Our case highlights the importance to consider Cryptococcus among the etiologies of meningitis in immunocompetent patients if more common etiologies are excluded.

Declaration of competing interest

There are no conflicts of interest for any authors.
  13 in total

1.  Cryptococcal cerebellitis after chemotherapy and autologous stem cell re-infusion in a patient with multiple myeloma.

Authors:  W Fickweiler; M J H Aries; R H Enting; E Vellenga; J De Keyser
Journal:  J Neurol       Date:  2009-02-16       Impact factor: 4.849

2.  [Neuromeningeal cryptococcosis in patients infected with HIV at Agadir regional hospital, (Souss-Massa, Morocco)].

Authors:  S Chadli; M Aghrouch; N Taqarort; M Malmoussi; Z Ouagari; F Moustaoui; M Bourouache; S Oulkheir
Journal:  J Mycol Med       Date:  2017-11-11       Impact factor: 2.391

Review 3.  [Cryptococcosis during HIV infection].

Authors:  M El Fane; L Badaoui; A Ouladlahsen; M Sodqi; L Marih; A Chakib; K Marhoum El Filali
Journal:  J Mycol Med       Date:  2015-10-26       Impact factor: 2.391

4.  Disseminated cryptococcosis in bone marrow.

Authors:  Ludovic Suner; Stephanie Mathis
Journal:  Blood       Date:  2014-05-15       Impact factor: 22.113

5.  Invasive granulomatous cryptococcal sinusitis in an adult with multiple myeloma.

Authors:  Richard A Ferraro; Jana Ivanidze; Elizabeth Margolskee; Hamilton Tsang; Theresa Sconomiglio; Yuliya S Jhanwar
Journal:  Clin Imaging       Date:  2016-10-17       Impact factor: 1.605

Review 6.  Cryptococcosis.

Authors:  Eileen K Maziarz; John R Perfect
Journal:  Infect Dis Clin North Am       Date:  2016-03       Impact factor: 5.982

7.  [Cryptococcosis: a potential aetiology of facial ulceration].

Authors:  R Béogo; J-B Andonaba; S Bamba; V Konségré; B Diallo; A Traoré
Journal:  J Mycol Med       Date:  2014-12       Impact factor: 2.391

8.  [Disseminated cryptococcosis in an immunocompetent patient].

Authors:  B Elkhihal; A Hasnaoui; I Ghfir; A Moustachi; S Aoufi; M Lyagoubi
Journal:  J Mycol Med       Date:  2015-07-27       Impact factor: 2.391

9.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

Authors:  John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

10.  Disseminated Cryptococcosis in a Patient with Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone.

Authors:  Shuku Sato; Emiko Kambe; Yotaro Tamai
Journal:  Intern Med       Date:  2018-11-19       Impact factor: 1.271

View more
  1 in total

1.  Cryptococcosis in a patient with multiple myeloma receiving pomalidomide: a case report and literature review.

Authors:  Daniel B Chastain; Sahand Golpayegany; Andrés F Henao-Martínez; Brittany T Jackson; Laura Leigh Stoudenmire; Kaye Bell; Kayla R Stover; Carlos Franco-Paredes
Journal:  Ther Adv Infect Dis       Date:  2022-07-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.